- |||||||||| GSK2879552 / GSK
Phase classification, Enrollment change, Trial termination, Combination therapy: Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - May 14, 2019 P1/2, N=7, Terminated, N=50 --> 0 | Terminated --> Withdrawn Phase classification: P2 --> P1/2 | N=74 --> 7 | Recruiting --> Terminated; The risk benefit in the study population does not favor continuation of the study
- |||||||||| Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm
Trial completion: Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) (clinicaltrials.gov) - Apr 20, 2019 P3, N=260, Completed, N=40 --> 13 | Trial completion date: Dec 2021 --> Aug 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Aug 2018; Study drug supply expired and could not be renewed. Active, not recruiting --> Completed
- |||||||||| sEphB4-HSA / VasGene, National Cancer Institute
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent (clinicaltrials.gov) - Apr 18, 2019 P2, N=7, Terminated, Active, not recruiting --> Completed | Trial completion date: Feb 2021 --> Apr 2019 | Trial primary completion date: Feb 2020 --> Apr 2019 N=12 --> 7 | Trial completion date: Apr 2021 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Apr 2020 --> Mar 2019; Lack of funding
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Trial completion date, Trial termination, Post-transplantation: Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT (clinicaltrials.gov) - Apr 5, 2019 P2, N=32, Terminated, N=12 --> 7 | Trial completion date: Apr 2021 --> Mar 2019 | Recruiting --> Terminated | Trial primary completion date: Apr 2020 --> Mar 2019; Lack of funding N=60 --> 32 | Trial completion date: Jul 2020 --> Apr 2019 | Suspended --> Terminated; Poor recruitment
- |||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, Post-transplantation: PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis (clinicaltrials.gov) - Apr 4, 2019 P1/2, N=20, Completed, N=60 --> 32 | Trial completion date: Jul 2020 --> Apr 2019 | Suspended --> Terminated; Poor recruitment Active, not recruiting --> Completed
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Apr 2, 2019
P=N/A, N=23, Terminated, Trial completion date: Apr 2020 --> Apr 2025 | Trial primary completion date: Dec 2018 --> Dec 2022 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Mar 5, 2019 P2, N=92, Completed, N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed
- |||||||||| Jakafi (ruxolitinib) / Incyte, Farydak (panobinostat) / Secura Bio
Trial completion, Trial completion date, Trial primary completion date, Epigenetic controller: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) (clinicaltrials.gov) - Mar 4, 2019 P1/2, N=20, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> May 2018 | Trial primary completion date: Feb 2019 --> May 2018
- |||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML (clinicaltrials.gov) - Feb 28, 2019 P1/2, N=49, Completed, Active, not recruiting --> Completed | Trial completion date: Feb 2019 --> May 2018 | Trial primary completion date: Feb 2019 --> May 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jul 2018
- |||||||||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Roche
Enrollment change, Trial termination: Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Feb 26, 2019 P2, N=20, Terminated, Active, not recruiting --> Completed | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016 N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections.
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 28, 2019
P1/2, N=96, Completed, Completed --> Terminated; No bone lesions detected and poor accrual Active, not recruiting --> Completed | N=52 --> 96 | Trial completion date: Apr 2019 --> Dec 2018 | Trial primary completion date: Apr 2019 --> Dec 2018
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial completion date, Trial termination: DANIN: Dasatinib Versus Nilotinib for Treatment Na (clinicaltrials.gov) - Jan 23, 2019 P3, N=10, Terminated, Recruiting --> Completed | Trial completion date: Jun 2018 --> Jan 2018 | Trial primary completion date: Jun 2018 --> Jan 2018 N=50 --> 10 | Trial completion date: Aug 2022 --> Sep 2018 | Recruiting --> Terminated; Protocol Deviation
- |||||||||| Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jan 15, 2019 P2, N=11, Completed, Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2020 --> Sep 2021 Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017
- |||||||||| pioglitazone / Generic mfg.
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (clinicaltrials.gov) - Jan 9, 2019 P2, N=9, Terminated, Recruiting --> Completed | N=33 --> 11 | Trial completion date: Dec 2019 --> Dec 2017 | Trial primary completion date: Jul 2019 --> Dec 2017 N=26 --> 9 | Trial completion date: May 2021 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: May 2021 --> Jul 2018
- |||||||||| PLX51107 / Daiichi Sankyo
Trial completion date, Trial termination, Trial primary completion date, Metastases: A Study of PLX51107 in Advanced Malignancies (clinicaltrials.gov) - Dec 24, 2018 P1b/2a, N=50, Terminated, N=40 --> 10 Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018; Business Decision
- |||||||||| Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Dec 13, 2018
P=N/A, N=592, Completed, Trial completion date: May 2019 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2019 --> Sep 2018; Business Decision Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018
- |||||||||| Trial termination: New York Blood Center National Cord Blood Program (clinicaltrials.gov) - Nov 2, 2018
P1, N=4476, Terminated, Trial primary completion date: May 2018 --> Dec 2017 Recruiting --> Terminated; Study NCT01656603 supersedes this study; FDA IND 6637
- |||||||||| Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Nov 2, 2018 P2, N=7, Terminated, Recruiting --> Terminated; Study NCT01656603 supersedes this study; FDA IND 6637 N=100 --> 7 | Trial completion date: Oct 2023 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jul 2018; Original principal investigator left institution
- |||||||||| talacotuzumab (JNJ-56022473) / J&J
Enrollment change, Trial termination, Trial primary completion date: SAMBA: Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY (clinicaltrials.gov) - Oct 25, 2018 P2, N=25, Terminated, Recruiting --> Completed | N=50 --> 15 N=43 --> 25 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Oct 2018; Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined.
- |||||||||| lenalidomide / Generic mfg.
Enrollment change, Trial termination: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Oct 18, 2018 P2, N=32, Terminated, N=43 --> 25 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Oct 2018; Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined. N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy
- |||||||||| cyclophosphamide / Generic mfg.
Trial completion, Phase classification, Trial completion date, Trial primary completion date, Post-transplantation: Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) - Oct 17, 2018 P1, N=127, Completed, N=48 --> 32 | Active, not recruiting --> Terminated; Lack of efficacy Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2022 --> Mar 2018 | Trial primary completion date: Jun 2019 --> Mar 2018
|